Skip to main content
SpringerLink
Log in

Introduction

  • Review Article
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Références

  1. Le Chevalier T, Brown A, Natale R, et al. Gemcitablne In the treatment of non-small cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data. Lung Cancer 2003; 41: 70

    Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, et al. for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8

    Article  PubMed  CAS  Google Scholar 

  3. Stewart LA, Parmar MK. Meta-analysis of the literature or of Individual patient data: is there a difference ? Lancet 1993; 341: 418–22

    Article  PubMed  CAS  Google Scholar 

  4. Scagliotti G, De Marinis F, Rinaldi M, et al. for the Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung cancer. J Clin Oncol 2002; 20: 4285–91

    Article  PubMed  CAS  Google Scholar 

  5. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage Mb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003; 41(Suppl. 2): 65

    Article  Google Scholar 

  6. Dunsford M, Mead GM, Bateman A, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10: 943–7

    Article  PubMed  CAS  Google Scholar 

  7. Kosmidis PA, Bacoyiannis C, Mylonakis N, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis. Proc Am Assoc Clin Oncol 2000; 18: A1908

    Google Scholar 

  8. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21: 3909–17

    Article  PubMed  CAS  Google Scholar 

  9. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478

    Article  PubMed  CAS  Google Scholar 

  10. Treat J, Chandra BP, Edelman M, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage MB, IV) non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41(Suppl. 2): 64

    Article  Google Scholar 

  11. Pujol JL, Breton JL, Riviere A, et al. Gemcitabine-docetaxel (GD) versus vinorelbine-cisplatin (VC) in advanced non-small cell lung cancer (NSCLC). A phase III study. Lung Cancer 2003; 41(Suppl. 2): 65

    Article  Google Scholar 

  12. Mezger J, Pilz LR, Koschel G, et al. Single-agent gemcitabine (G) and docetaxel (D) given sequentially every 3 weeks in advanced NSCLC: final results and quality of life assessment of a randomised phase II study show effective treatment. Lung Cancer 2003; 41(S2): 64

    Article  Google Scholar 

  13. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelloma. J Clin Oncol 2003; 21: 2636–44

    Article  PubMed  CAS  Google Scholar 

  14. Shepherd FA, Pereira JR, Von Pawel J, et al. A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy. Lung Cancer 2003; 41Suppl. 2: 4

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hospitalier Universitaire de Montpellier, Montpellier, France

    Jean-Louis Pujol

Authors
  1. Jean-Louis Pujol
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pujol, JL. Introduction. Am J Cancer 3 (Suppl 1), 1–4 (2004). https://doi.org/10.2165/00024669-200403991-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200403991-00001

Search

Navigation